• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎瘙痒管理的当前临床选择

Current Clinical Options for the Management of Itch in Atopic Dermatitis.

作者信息

Lipman Zoe M, Labib Angelina, Yosipovitch Gil

机构信息

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

Clin Cosmet Investig Dermatol. 2021 Aug 3;14:959-969. doi: 10.2147/CCID.S289716. eCollection 2021.

DOI:10.2147/CCID.S289716
PMID:34377004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8349193/
Abstract

Pruritus is the most burdensome and prevalent symptom in patients suffering from atopic dermatitis. Treating atopic itch has historically been a challenge due to multiple underlying mechanisms within its pathogenesis and an incomplete understanding of them. In recent years, our understanding of these mechanisms have increased tremendously and subsequently, new treatments have reached the market that target the pathophysiology of atopic itch from different angles. In addition, there are several promising new treatments currently in development and trials. In the current article, we discuss these currently available treatment options, their available evidence and efficacy, and highlight some of the more recent advancements in the field.

摘要

瘙痒是特应性皮炎患者最沉重且普遍的症状。由于特应性瘙痒发病机制中的多种潜在机制以及对这些机制的不完全理解,治疗特应性瘙痒在历史上一直是一项挑战。近年来,我们对这些机制的理解有了极大的提高,随后,有针对特应性瘙痒病理生理学的不同角度的新疗法进入市场。此外,目前还有几种有前景的新疗法正在研发和试验中。在本文中,我们讨论了这些目前可用的治疗选择、它们的现有证据和疗效,并强调了该领域的一些最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8349193/68bbc6bc0ea8/CCID-14-959-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8349193/68bbc6bc0ea8/CCID-14-959-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8349193/68bbc6bc0ea8/CCID-14-959-g0001.jpg

相似文献

1
Current Clinical Options for the Management of Itch in Atopic Dermatitis.特应性皮炎瘙痒管理的当前临床选择
Clin Cosmet Investig Dermatol. 2021 Aug 3;14:959-969. doi: 10.2147/CCID.S289716. eCollection 2021.
2
Emerging treatments for itch in atopic dermatitis: A review.特应性皮炎瘙痒的新兴治疗方法:综述。
J Am Acad Dermatol. 2023 Aug;89(2):338-344. doi: 10.1016/j.jaad.2023.04.057. Epub 2023 May 6.
3
Characterization of the effects on pruritus by novel treatments for atopic dermatitis.新型特应性皮炎治疗药物对瘙痒影响的特征描述。
J Dtsch Dermatol Ges. 2022 Feb;20(2):150-156. doi: 10.1111/ddg.14678. Epub 2021 Dec 27.
4
The effects of treatment on itch in atopic dermatitis.特应性皮炎瘙痒的治疗效果。
Dermatol Ther. 2013 Mar-Apr;26(2):110-9. doi: 10.1111/dth.12032.
5
What causes itch in atopic dermatitis?特应性皮炎中的瘙痒是由什么引起的?
Curr Allergy Asthma Rep. 2008 Jul;8(4):306-11. doi: 10.1007/s11882-008-0049-z.
6
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.阿泊替尼治疗早期瘙痒反应与中重度特应性皮炎患者的后期疗效结局相关:随机 III 期 JADE COMPARE 试验的亚组分析。
Am J Clin Dermatol. 2023 Jan;24(1):97-107. doi: 10.1007/s40257-022-00738-4. Epub 2022 Dec 13.
7
Itch in Atopic Dermatitis - What Is New?特应性皮炎中的瘙痒——有哪些新进展?
Front Med (Lausanne). 2021 May 7;8:644760. doi: 10.3389/fmed.2021.644760. eCollection 2021.
8
Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions.特应性皮炎瘙痒的发病机制:神经免疫相互作用的新作用。
Eur J Dermatol. 2023 Aug 1;33(4):343-349. doi: 10.1684/ejd.2023.4514.
9
When topical therapy of atopic dermatitis fails: a guide for the clinician.当特应性皮炎的局部治疗失败时:临床医生的指南。
Expert Rev Clin Immunol. 2021 Dec;17(12):1245-1256. doi: 10.1080/1744666X.2021.2000390. Epub 2021 Nov 11.
10
Recent studies of cutaneous nociception in atopic and non-atopic subjects.近期针对特应性和非特应性受试者皮肤痛觉的研究。
J Dermatol. 1999 Feb;26(2):77-86. doi: 10.1111/j.1346-8138.1999.tb03516.x.

引用本文的文献

1
Type 2 Inflammation and Its Role in Dermatologic Diseases.2型炎症及其在皮肤病中的作用。
Int J Dermatol. 2025 Jun;64(6):978-991. doi: 10.1111/ijd.17707. Epub 2025 Mar 22.
2
Novel drug delivery systems in topical treatment of atopic dermatitis.用于特应性皮炎局部治疗的新型药物递送系统。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 13. doi: 10.1007/s00210-025-04002-4.
3
Practical guide for the diagnosis and treatment of localized and generalized cutaneous pruritus (chronic itch with no underlying pruritic dermatosis).

本文引用的文献

1
P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications.P2X3受体配体:结构特征与潜在治疗应用
Front Pharmacol. 2021 Apr 13;12:653561. doi: 10.3389/fphar.2021.653561. eCollection 2021.
2
An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.评估地肤利法林作为终末期肾病中重度瘙痒治疗选择的效果。
Expert Opin Pharmacother. 2021 Apr;22(5):549-555. doi: 10.1080/14656566.2020.1849142. Epub 2020 Dec 14.
3
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
局限性和全身性皮肤瘙痒症(无潜在瘙痒性皮肤病的慢性瘙痒)的诊断与治疗实用指南
J Dermatol. 2025 Feb;52(2):204-220. doi: 10.1111/1346-8138.17565. Epub 2024 Dec 12.
4
Kappa opioid agonists in the treatment of itch: just scratching the surface?κ阿片受体激动剂在瘙痒治疗中的应用:只是触及表面?
Itch (Phila). 2023 Oct-Dec;8(4). doi: 10.1097/itx.0000000000000072. Epub 2023 Dec 6.
5
A phase IV, randomised, double-blind, controlled, parallel group trial to evaluate the effectiveness and safety of Balneum Plus versus emollient in the treatment of chronic kidney disease-associated pruritus in haemodialysis patients.一项IV期随机双盲对照平行组试验,旨在评估Balneum Plus与润肤剂治疗血液透析患者慢性肾脏病相关性瘙痒的有效性和安全性。
Clin Kidney J. 2023 Mar 29;16(8):1307-1315. doi: 10.1093/ckj/sfad066. eCollection 2023 Aug.
6
Fc Epsilon RI-Neuroimmune Interplay in Pruritus Triggered by Particulate Matter in Atopic Dermatitis Patients.FcεRI-神经免疫在特应性皮炎患者因颗粒物引发瘙痒中的相互作用。
Int J Mol Sci. 2023 Jul 24;24(14):11851. doi: 10.3390/ijms241411851.
7
Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients.缓解颈部肌肉紧张可改善心理压力及中重度特应性皮炎症状:20例患者的病例系列研究
Dermatol Ther (Heidelb). 2022 Oct;12(10):2383-2395. doi: 10.1007/s13555-022-00814-x. Epub 2022 Sep 21.
8
D-galactose Intake Alleviates Atopic Dermatitis in Mice by Modulating Intestinal Microbiota.D-半乳糖摄入通过调节肠道微生物群减轻小鼠特应性皮炎
Front Nutr. 2022 Jun 21;9:895837. doi: 10.3389/fnut.2022.895837. eCollection 2022.
9
Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date.使用乌帕替尼治疗特应性皮炎——迄今的证据
Clin Cosmet Investig Dermatol. 2022 Jun 8;15:1065-1072. doi: 10.2147/CCID.S295672. eCollection 2022.
10
Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.布鲁顿酪氨酸激酶抑制 - 一种新兴的免疫介导性皮肤病治疗策略。
Allergy. 2022 Aug;77(8):2355-2366. doi: 10.1111/all.15261. Epub 2022 Feb 28.
他卡西醇治疗银屑病:新型芳香烃受体调节剂独特作用机制的综述。
J Am Acad Dermatol. 2021 Apr;84(4):1059-1067. doi: 10.1016/j.jaad.2020.10.085. Epub 2020 Nov 3.
4
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017.特应性皮炎的全球负担:1990 - 2017年全球疾病负担研究的经验教训
Br J Dermatol. 2021 Feb;184(2):304-309. doi: 10.1111/bjd.19580. Epub 2020 Nov 29.
5
Dupilumab use in atopic dermatitis and beyond in skin diseases.度普利尤单抗在特应性皮炎及皮肤病中的应用。
Immunotherapy. 2020 Dec;12(17):1221-1235. doi: 10.2217/imt-2020-0175. Epub 2020 Sep 7.
6
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.阿布昔替尼治疗成人和青少年中重度特应性皮炎的疗效和安全性(JADE MONO-1):一项多中心、双盲、随机、安慰剂对照、3 期临床试验。
Lancet. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7.
7
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.针对伴有瘙痒的特应性皮炎的 Nemolizumab 与局部治疗药物的试验。
N Engl J Med. 2020 Jul 9;383(2):141-150. doi: 10.1056/NEJMoa1917006.
8
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.阿巴西普治疗中重度特应性皮炎患者的疗效和安全性:一项随机临床试验。
JAMA Dermatol. 2020 Aug 1;156(8):863-873. doi: 10.1001/jamadermatol.2020.1406.
9
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.与环孢素A和甲氨蝶呤相比,度普利尤单抗在一大群难治性成年特应性皮炎患者中的两年药物生存率:来自BioDay注册研究的结果
Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5.
10
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.度普利尤单抗治疗可使中度至重度特应性皮炎的青少年和成人瘙痒症状得到早期且持续的改善:随机3期研究SOLO 1、SOLO 2、AD ADOL和CHRONOS的分析。
J Am Acad Dermatol. 2020 Jun;82(6):1328-1336. doi: 10.1016/j.jaad.2020.02.060. Epub 2020 Mar 3.